The FDA endorsement for Phase 3 initiation of sutacimig in GT is the most significant catalyst, watch for trial enrollment updates and data readouts in late 2026/early 2027. HMB-002 and HMB-003 data readouts in late 2026/early 2027 are secondary catalysts. The strong cash runway removes near-term financing risk.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $49.87entry
- T+1 · 3mo ago +7.24%α +6.99% · $53.48
- T+5 · 3mo ago +5.15%α +5.56% · $52.44
- T+20 · 2mo ago −10.77%α −9.71% · $44.50
- T+60 · 13d ago −12.85%α −12.72% · $43.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line with consensus of $-0.82. The company highlighted FDA endorsement to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia, positive Phase 1/2 data for HMB-002 in Von Willebrand Disease, and unveiled a new preclinical program HMB-003. Cash position strengthened to $457.5M post-IPO, providing runway into 2029. The stock will move on pipeline catalysts rather than the pre-revenue financials.
Key Financial Metrics
Key Facts
- Net loss of $24.2M ($0.80/share) vs consensus $-0.82, in line
- Cash, cash equivalents, and marketable securities totaled $457.5M as of June 30, 2026, up from $163.5M at March 31, 2026
- FDA endorsed clinical data package for sutacimig as sufficient to proceed to Phase 3 pivotal trial in Glanzmann thrombasthenia; Phase 3 initiation planned 2H 2026
- HMB-002 Phase 1/2 data showed 2.4-fold increase in VWF and FVIII, with 8 of 9 evaluable patients having zero treated bleeds in 28 days
- Unveiled HMB-003, a novel peptide-based plasmin inhibitor for heavy menstrual bleeding; first-in-human studies planned 2H 2026
- R&D expenses $20.3M (Q2 2026) vs $12.9M (Q2 2025), reflecting clinical program advancement
Financial Impact
Q2 2026 net loss of $24.2M ($0.80/share) vs consensus $-0.82, in line. Cash runway extended into 2029 with $457.5M post-IPO.
Risk Factors
- Phase 3 trial failure or safety signal in sutacimig
- Competition from existing therapies (recombinant Factor VIIa, platelet transfusions)
- Dilution risk if additional capital is needed beyond current runway
- Clinical trial enrollment delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343421 |
| Document: d180684d8k.htm | 0001193125-26-343421 |
| Document: 0001193125-26-343421-index-headers.html | 0001193125-26-343421 |
| Document: 0001193125-26-343421-index.html | 0001193125-26-343421 |
| Document: 0001193125-26-343421.txt | 0001193125-26-343421 |
| 8-K Data (Synthetic) | 0001193125-26-343421 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Viewing Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers